Ro-3306

For research use only. Not for use in humans.

目录号:S7747

Ro-3306 Chemical Structure

CAS No. 872573-93-8

RO-3306是一种ATP竞争性的选择性 CDK1 抑制剂,Ki 为20 nM,选择性是其他各种人类激酶的15倍多。RO-3306可增强p53介导的 Bax 激活和线粒体的凋亡。

规格 价格 库存 购买数量  
RMB 1049.39 现货
RMB 3270.12 现货
RMB 8151.52 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Ro-3306发表文献57篇:

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述 RO-3306是一种ATP竞争性的选择性 CDK1 抑制剂,Ki 为20 nM,选择性是其他各种人类激酶的15倍多。RO-3306可增强p53介导的 Bax 激活和线粒体的凋亡。
靶点
CDK1 [1]
(Cell-free assay)
PKCδ [1]
(Cell-free assay)
SGK [1]
(Cell-free assay)
ERK [1]
(Cell-free assay)
20 nM(Ki) 318 nM(Ki) 497 nM(Ki) 1980 nM(Ki)
体外研究

RO-3306抑制CDK1/cyclin B1,CDK1/cyclin A,CDK2/cyclin E,和CDK4/cyclin D活性,Ki分别为35 nM,110 nM,340 nM,和>2000 nM。HCT116,SW480,和HeLa细胞用RO-3306处理20小时导致细胞周期完全阻滞在G2/M期。HCT116和SW480的增殖被RO-3306有效阻断。RO-3306似乎在癌细胞(HCT116和SW480)中比在非致瘤性细胞(MCF 10A和MCF 12A)中具有更强的促凋亡作用。[1] 10 μM 浓度的RO-3306有效阻止卵母细胞成熟。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human NCI-SNU-1 cell M3jT[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkXFTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjd|MEm1JO69VQ>? MmKwV2FPT0WU
human H460a cells MWDQdo9tcW[ncnH0bY9vKGG|c3H5 NFTiZYZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi0OlBiKGOnbHzzMEBKSzVyPUGuNFQh|ryP MmjjNVc{ODN2MkG=
human MDA435 cells M17hdnBzd2yrZnXyZZRqd25iYYPzZZk> NV\U[|dvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGE1OzViY3XscJMtKEmFNUC9NU4yPCEQvF2= NHm1dYgyPzNyM{SyNS=>
human HCT116 cells M33IdHBzd2yrZnXyZZRqd25iYYPzZZk> M{TiXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzMEBKSzVyPUGuNVQh|ryP MXexO|MxOzR{MR?=
human H4 cell NGG0ZYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYfJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5zNUi3OUDPxE1? NF\LeotUSU6JRWK=
human PA-1 cell NYSz[o1mT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWLVSnp1UW6qaXLpeIlwdiCxZjDoeY1idiCSQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOjZ3NDFOwG0> MYnTRW5ITVJ?
human T98G cell NEf3TIRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkniTY5pcWKrdHnvckBw\iCqdX3hckBVQTiJIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zOlgyOiEQvF2= MV3TRW5ITVJ?
human SW1710 cell NIf0fo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWTJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlE1ODhizszN MojwV2FPT0WU
human U251 cell NULpPW1NT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUXlSJlMUW6qaXLpeIlwdiCxZjDoeY1idiCXMkWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43Ozd5MTFOwG0> NVfFNY85W0GQR1XS
human ALL-PO cell M13ZWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{XvZ2lvcGmkaYTpc44hd2ZiaIXtZY4hSUyOLWDPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZnwxIxiSVO1NF0yNjlyOEGzJO69VQ>? NVTuVHlSW0GQR1XS
human RKO cells M4\Pb3Bzd2yrZnXyZZRqd25iYYPzZZk> MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKNTzDj[YxteyxiSVO1NF0zKM7:TR?= NXz3R|Z2OTd|MEO0NlE>
human SK-N-DZ cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NY\odWpCUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWRbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yMUi3OkDPxE1? M1jzRnNCVkeHUh?=
human A4-Fuk cell M4fVcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2TYXmlvcGmkaYTpc44hd2ZiaIXtZY4hSTRvRoXrJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4xPTZyNDFOwG0> NYLENo0yW0GQR1XS
human SW480 cells M1nTT3Bzd2yrZnXyZZRqd25iYYPzZZk> NGq2RZdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPXOFgxKGOnbHzzMEBKSzVyPUKuNkDPxE1? NFHhVm0yPzNyM{SyNS=>
human 639-V cell M3e1c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn:wTY5pcWKrdHnvckBw\iCqdX3hckA3OzlvVjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNlc2OzdizszN NHfwfZlUSU6JRWK=
human Hs-578-T cell MoH5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NELF[GpKdmirYnn0bY9vKG:oIHj1cYFvKEi|LUW3PE1VKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5{N{e5PUDPxE1? NF7OOJZUSU6JRWK=
human UM-UC-3 cell MmK1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKGi3bXHuJHVONVWFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4Phfg+9lCCLQ{WwQVIvPzN7M{[g{txO MUTTRW5ITVJ?
human BPH-1 cell NIrPVlNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4jTbGlvcGmkaYTpc44hd2ZiaIXtZY4hSlCKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlk4PDV3IN88US=> M2TaTHNCVkeHUh?=
human 5637 cell NVrJcYp2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mkf4TY5pcWKrdHnvckBw\iCqdX3hckA2PjN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6wPFU{OiEQvF2= M4G4[3NCVkeHUh?=
human 8-MG-BA cell NX\nbHpST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{ixUmlvcGmkaYTpc44hd2ZiaIXtZY4hQC2PRz3CRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F697zOIFnDOVA:Oy5zNEC0PUDPxE1? MW\TRW5ITVJ?
human HCT116 cells NYDwSGx[S3m2b4TvfIlkyqCjc4PhfS=> NWSzOZJQPSCmYYnz MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4Phfg+9lCCLQ{WwQVMvOiEQvF2= M2WwRVIzOzJ4MU[4
human LB1047-RCC cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{\0bWlvcGmkaYTpc44hd2ZiaIXtZY4hVEJzMES3MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwMkO1NFEh|ryP NVPtZo45W0GQR1XS
human KOSC-2 cell NEHWbVBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M165XWlvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{41PDZ4NkKg{txO MonLV2FPT0WU
human COR-L88 cell NX3UeodoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUfJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OOEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ4PTh|IN88US=> MYPTRW5ITVJ?
human PSN1 cell NXXK[oNJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHBUVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkGwPFA2KM7:TR?= MYXTRW5ITVJ?
human LXF-289 cell MnKxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGXYVoJKdmirYnn0bY9vKG:oIHj1cYFvKEy[Rj2yPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjJzN{[g{txO Mk\SV2FPT0WU
human MN-60 cell MnPaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWO5XZE1UW6qaXLpeIlwdiCxZjDoeY1idiCPTj22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOzd4MkOg{txO NGfYb3hUSU6JRWK=
human NEC8 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1zNemlvcGmkaYTpc44hd2ZiaIXtZY4hVkWFODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuOFcxPzZizszN NVTHVI11W0GQR1XS
human SJSA1 cells MkHRVJJwdGmoZYLheIlwdiCjc4PhfS=> NGXPZnNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPKV2EyKGOnbHzzMEBKSzVyPUSuOVUh|ryP M{LNNFE4OzB|NEKx
human NCI-H2405 cell NFK4NpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVjC[ZVpUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI1ODViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke0OFk{KM7:TR?= NI\tNGhUSU6JRWK=
human YH-13 cell M4\xVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXvKcYFoUW6qaXLpeIlwdiCxZjDoeY1idiC\SD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPzV5N{[g{txO MUfTRW5ITVJ?
human SK-MEL-2 cell M2TLdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1;wOWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjB7NkOyJO6ddQ>? M2HoVnNCVkeHUh?=
human NB13 cell NYDmWFVVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4G2VWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuN|I4QDZizszN NWqxV3p[W0GQR1XS
human GAMG cell NUTGdYZrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NU\aN|ByUW6qaXLpeIlwdiCxZjDoeY1idiCJQV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{PzF3IN88US=> MnWwV2FPT0WU
human NCI-H1792 cell M2S4RWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDd7NUSg{txO NFnu[VVUSU6JRWK=
human KP-4 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2nOc2lvcGmkaYTpc44hd2ZiaIXtZY4hU1BvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOlk5OjNizszN M4PNUnNCVkeHUh?=
human HGC-27 cell NWfyU2E6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUDJcohq[mm2aX;uJI9nKGi3bXHuJGhISy1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|MxPzdizszN NWfvZ4h{W0GQR1XS
human GCT cell M4\kWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1nlbmlvcGmkaYTpc44hd2ZiaIXtZY4hT0OWIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT64OVEzOSEQvF2= NH\rdZdUSU6JRWK=
human PFSK-1 cell Moj3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlzKTY5pcWKrdHnvckBw\iCqdX3hckBRTlONLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg3OTZ6IN88US=> NYf0fmZFW0GQR1XS
human A172 cell M1;XfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYrEVoNSUW6qaXLpeIlwdiCxZjDoeY1idiCDMUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46ODd7IN88US=> NVfQTW1xW0GQR1XS
human HO-1-N-1 cell M{CxdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmfYTY5pcWKrdHnvckBw\iCqdX3hckBJVy1zLV6tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTV2MkWg{txO NHXJW5VUSU6JRWK=
human HN cell NFPlN|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3HiVGlvcGmkaYTpc44hd2ZiaIXtZY4hUE5iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lkm3NFk4KM7:TR?= MYXTRW5ITVJ?
human IST-MES1 cell NGHs[WFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkezTY5pcWKrdHnvckBw\iCqdX3hckBKW1RvTVXTNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTd3MkGg{txO NELhc3FUSU6JRWK=
human TGW cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NW\2S|lWUW6qaXLpeIlwdiCxZjDoeY1idiCWR2egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlA2Pjh{IN88US=> NH:1SmNUSU6JRWK=
human COR-L23 cell NYK5UXRST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHuzRmNKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MNlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjN5M{Wg{txO NXjVOGtlW0GQR1XS
human D-566MG cell M4m2cmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkntTY5pcWKrdHnvckBw\iCqdX3hckBFNTV4Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44QDh5MzFOwG0> NHKxUoRUSU6JRWK=
human SKG-IIIa cell M1L4UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYjPe2N6UW6qaXLpeIlwdiCxZjDoeY1idiCVS1etTWlK[SClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwOEW1O|Ih|ryP MljiV2FPT0WU
human NCI-H446 cell M37Fb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWjPSHdzUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFQ1PiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEG4NUDPxE1? NHqycXBUSU6JRWK=
human KYSE-270 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX3GPI5CUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVI4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEO4O|Ih|ryP M2f0O3NCVkeHUh?=
human CAL-39 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M33QUmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{PTJ2IN88US=> M3X4[XNCVkeHUh?=
human IST-SL1 cell NH3pfpJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2jXZWlvcGmkaYTpc44hd2ZiaIXtZY4hUVOWLWPMNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPDN|NEmg{txO NVTlcHVGW0GQR1XS
human SF539 cell M4LaPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnH4TY5pcWKrdHnvckBw\iCqdX3hckBUTjV|OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuOVUyQTdizszN MW\TRW5ITVJ?
human TE-1 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIHEfVZKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlg6ODlzIN88US=> NVvHR5BmW0GQR1XS
human NB10 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoPTTY5pcWKrdHnvckBw\iCqdX3hckBPSjFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz65PFc2QCEQvF2= MnXMV2FPT0WU
human 8505C cell NEXDfHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4XPdGlvcGmkaYTpc44hd2ZiaIXtZY4hQDVyNVOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlk6QDF5IN88US=> M3y2VnNCVkeHUh?=
human DB cell M4f1cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWTpW|RuUW6qaXLpeIlwdiCxZjDoeY1idiCGQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNFEyOzFizszN NXzYW21[W0GQR1XS
human NCI-H28 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVXOSJlnUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QC53OUi4OEDPxE1? NGf5fppUSU6JRWK=
human LOXIMVI cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYr0[5FWUW6qaXLpeIlwdiCxZjDoeY1idiCOT2jJUXZKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QC54M{ewNUDPxE1? M1zrUnNCVkeHUh?=
human ME-180 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWThUldNUW6qaXLpeIlwdiCxZjDoeY1idiCPRT2xPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05NjhyM{m1JO69VQ>? M4\mdXNCVkeHUh?=
human ES3 cell NIPLPJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2rmNGlvcGmkaYTpc44hd2ZiaIXtZY4hTVN|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OT6xNlc6PCEQvF2= MVLTRW5ITVJ?
human SK-N-FI cell M3vvN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NETmb|NKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSmkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjRzNkm5JO69VQ>? MYjTRW5ITVJ?
human NBsusSR cell NEjKeHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjjR3hlUW6qaXLpeIlwdiCxZjDoeY1idiCQQoP1d3NTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTBwMkOxPEDPxE1? NVjCUIRIW0GQR1XS
human MCF7 cell M1vOZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MonyTY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUGuNVg1QSEQvF2= MXXTRW5ITVJ?
human A549 cell NHzLU4NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUPJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMT6yNFYh|ryP MkTuV2FPT0WU
human HuP-T4 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVnUWoR[UW6qaXLpeIlwdiCxZjDoeY1idiCKdWCtWFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC52MkexJO69VQ>? M4ey[nNCVkeHUh?=
human HSC-2 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX7VcnVqUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNDd6NEKg{txO M3zEfHNCVkeHUh?=
human A253 cell NE\XXlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGEzPTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNT6yPFM1KM7:TR?= NWfucmZkW0GQR1XS
human HCT-116 cell NWDESIlmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVfJcohq[mm2aX;uJI9nKGi3bXHuJHBENTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOD6wNFQ{KM7:TR?= M1XoXnNCVkeHUh?=
human HCT-116 cell MoTRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnfNTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVkvPjZ6IN88US=> M3LEWHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Cdk1 / Cdk1 / Cleaved PARP / Cleaved caspase-3 / p-p38 / Bad / Apaf1-1 / p-H2Ax / Bim / Bad; 

PubMed: 27385216     


OVCA-429 and OVCAR-3 were exposed to RO-3306 for 24 h in indicated dose dependent manner, (F) 10 uM RO-3306 for 12 h up to 48 h. The expression level of the indicated protein and the phosphorylated form of H2A.x and p38 were examined via Western blot analyses.

27385216
Immunofluorescence
PARP1 / Plk1 ; 

PubMed: 28069876     


Representative images of IF staining for PARP1 and Plk1 in 22RV1 cells treated with 0.3 mM mimosine for 20 h, 4 mM hydroxyurea for 24 h, 10 µM RO-3306 for 7 h or 200 ng/ml nocodazole (Noc) for 12 h.

28069876
Growth inhibition assay
Cell viability; 

PubMed: 27385216     


OVCA-429 and OVCAR-3 were exposed to RO-3306 in indicated time- and dose-dependent manner. Cell viability were measured via crystal violet assay. Results are the means ± S.E. n = 3. 

27385216

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

CDK试验:

CDK1 cyclin B1,CDK1 cyclin A,CDK2 cyclin E,和CDK4 cyclin D通过均相时间分辨荧光法在96孔格式中测量。实验缓冲液包含25 mM Hepes,6.25 mM MgCl2,0.003% Tween 20,0.3 mg/mL BSA,1.5 mM DTT,和如下含量的ATP: 162 μM (CDK1),90 mM (CDK2),或135 μM (CDK4)。CDK1和CDK2缓冲液包含10 mM MgCl2。测试化合物在20 μL实验缓冲液中稀释为它们终浓度的3倍,反应通过加入40 μL包含pRB底物(0.185μM)的试验缓冲液起始。板在37°C下连续搅拌培养30分钟,反应通过加入15 μL 含1.6μM 抗磷酸pRB抗体(Ser-780)的25 mM Hepes,24 mM EDTA,和0.2 mg/mL BSA终止。再振荡培育30分钟后,加入15μL 包含3nM Lance-Eu-W1024-labeledanti-rabbitIgG和60 nM Alophycocyanin共轭的抗-His-6 抗体的25 mM Hepes,以及0.5 mg/mL BSA,培育1小时。板在Victor-V多标阅读器上以340 nm激发波长和615 nm与665 nm发射波长读取数据。IC50值根据665 nm下的读数值进行计算,并归一化为615 nm下铕的读数值。Ki值根据公式Ki= IC50/(1 + S/Km )计算,其中S是试验中ATP浓度,Km是相对ATP的Michaelis-Menten常数。对激酶组的抑制活性通过IMAP测定技术确定。
细胞实验:[3]
- 合并
  • Cell lines: MDA-MB-231 细胞系
  • Concentrations: 20 μM
  • Incubation Time: 72 h
  • Method: 对数生长期细胞(25,000)接种于96孔板,在37℃培养箱中与CO2一起培养,24小时后,给予不同浓度RO-3306以测定达到50%生长抑制(IC50)的药物浓度。MTT (20 μL,包含5mg/mL储备溶液的生理盐水)加入每孔中,细胞培养4小时。移除上清液,来自活细胞的甲瓒晶体溶解在200 μL无水DMSO中。吸光度使用550模式酶标仪在565 nm波长下检测。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 13 mg/mL warmed (36.98 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 351.45
化学式

C18H13N3OS2

CAS号 872573-93-8
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

CDK Signaling Pathway Map

相关CDK产品

Tags: 购买Ro-3306 | Ro-3306供应商 | 采购Ro-3306 | Ro-3306价格 | Ro-3306生产 | 订购Ro-3306 | Ro-3306代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID